A G-quadruplex stabilizer, CX-5461 combined with two immune checkpoint inhibitors enhances in vivo therapeutic efficacy by increasing PD-L1 expression in colorectal cancer

G-quadruplexes: a promising target for cancer therapy

(2021) Nils Kosiol et al.   Molecular Cancer

CX-5461 Sensitizes DNA Damage Repair–proficient Castrate-resistant Prostate Cancer to PARP Inhibition

(2021) Mitchell G. Lawrence et al.   MOLECULAR CANCER THERAPEUTICS

The chemotherapeutic CX-5461 primarily targets TOP2B and exhibits selective activity in high-risk neuroblastoma

(2021) Min Pan et al.   Nature Communications

CX-5461 Treatment Leads to Cytosolic DNA-Mediated STING Activation in Ovarian Cancer

(2021) Robert Cornelison et al.   Cancers

The primary mechanism of cytotoxicity of the chemotherapeutic agent CX-5461 is topoisomerase II poisoning

(2020) Peter M. Bruno et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Nonenzymatic function of Aldolase A downregulates miR-145 to promote the Oct4/DUSP4/TRAF4 axis and the acquisition of lung cancer stemness

(2020) Yu-Chan Chang et al.   Cell Death & Disease

Predictive biomarkers for cancer immunotherapy with immune checkpoint inhibitors

(2020) Rilan Bai et al.   Biomarker Research

Tumor Mutational Burden as a Predictor of Immunotherapy Response: Is More Always Better?

(2020) John H. Strickler et al.   CLINICAL CANCER RESEARCH

Pembrolizumab in Microsatellite-Instability–High Advanced Colorectal Cancer

(2020) Thierry André et al.   NEW ENGLAND JOURNAL OF MEDICINE

Immunotherapy in colorectal cancer: rationale, challenges and potential

(2019) Karuna Ganesh et al.   Nature Reviews Gastroenterology & Hepatology

Folfiri-Aflibercept vs. Folfiri-Bevacizumab as Second Line Treatment of RAS Mutated Metastatic Colorectal Cancer in Real Practice

(2019) Alessandro Ottaiano et al.   Frontiers in Oncology

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression

(2019) Angel Garcia-Diaz et al.   Cell Reports

Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer

(2018) Michael J. Overman et al.   JOURNAL OF CLINICAL ONCOLOGY

Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors

(2018) Ming Yi et al.   Molecular Cancer

Damage-Associated Molecular Patterns in Inflammatory Diseases

(2018) Jong Seong Roh et al.   Immune Network

Tumor-Derived cGAMP Triggers a STING-Mediated Interferon Response in Non-tumor Cells to Activate the NK Cell Response

(2018) Assaf Marcus et al.   IMMUNITY

Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer

(2017) Alan P. Venook et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

CX-5461 is a DNA G-quadruplex stabilizer with selective lethality in BRCA1/2 deficient tumours

(2017) Hong Xu et al.   Nature Communications

Regulation and function of the cGAS–STING pathway of cytosolic DNA sensing

(2016) Qi Chen et al.   NATURE IMMUNOLOGY

Prognostic and predictive biomarkers in metastatic colorectal cancer anti-EGFR therapy

(2016) Cristiana Lo Nigro et al.   WORLD JOURNAL OF GASTROENTEROLOGY

Inhibition of RNA polymerase I transcription initiation by CX-5461 activates non-canonical ATM/ATR signaling

(2016) Jaclyn Quin et al.   Oncotarget

Systematic review of the predictive effect of MSI status in colorectal cancer patients undergoing 5FU-based chemotherapy

(2015) Elizabeth M Webber et al.   BMC CANCER

PD-1 Blockade in Tumors with Mismatch-Repair Deficiency

(2015) Dung T. Le et al.   NEW ENGLAND JOURNAL OF MEDICINE

Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma

(2015) J. R. Devlin et al.   Cancer Discovery

rRNA synthesis inhibitor, CX-5461, activates ATM/ATR pathway in acute lymphoblastic leukemia, arrests cells in G2 phase and induces apoptosis

(2015) Sandeep S. Negi et al.   Oncotarget

Colorectal cancer

(2013) Hermann Brenner et al.   LANCET

Panitumumab–FOLFOX4 Treatment and RAS Mutations in Colorectal Cancer

(2013) Jean-Yves Douillard et al.   NEW ENGLAND JOURNAL OF MEDICINE

Inhibition of RNA Polymerase I as a Therapeutic Strategy to Promote Cancer-Specific Activation of p53

(2012) Megan J. Bywater et al.   CANCER CELL

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

(2012) Axel Grothey et al.   LANCET

Colon cancer

(2010) Roberto Labianca et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Cross-regulation of Signaling Pathways by Interferon-γ: Implications for Immune Responses and Autoimmune Diseases

(2009) Xiaoyu Hu et al.   IMMUNITY

Unphosphorylated STAT1 prolongs the expression of interferon-induced immune regulatory genes

(2009) H. Cheon et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Recruitment of Stat1 to chromatin is required for interferon-induced serine phosphorylation of Stat1 transactivation domain

(2008) Iwona Sadzak et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA